Seeking Alpha

QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Boston Therapeutics, Inc. (BTHE) Heads Into 2014 With Strong, Experienced Leadership 0 comments
    Jan 13, 2014 6:00 PM | about stocks: BTHE

    Boston Therapeutics is developing a pipeline of novel compounds to address unmet medical needs in diabetes. The company's current product pipeline is focused on developing and commercializing the therapeutic molecules PAZ320 for patients with diabetes; and IPOXYNT for a wide rand of indications such as anemia and blood loss (injury), cardiovascular disease, and surgical blood supplementation.

    Boston Therapeutics' technology platform in applied carbohydrate chemistry has been pioneered by company CEO Dr. David Platt, who for the last 20 years has worked alongside scientific collaborators to safely address medical needs for oral and injectable applications.

    Dr. Platt is recognized worldwide as an expert in carbohydrate chemistry and has led two drug candidates from concept to human clinical trials. He also founded three publicly traded companies: Pro-Pharmaceuticals, Inc., SafeScience, Inc., and International Gene Group. Dr. Platt's guidance is supported by an executive management team with more than 100 years of combined experience.

    Providing additional expertise, Boston Therapeutics has established a scientific advisory team with extensive expertise in complex carbohydrate chemistry, regulatory, and clinical development, with multiple submissions and approvals to U.S. Food and Drug Administration.

    Under this leadership, Boston Therapeutics anticipates initiating a pivotal phase 3 study of PAZ320. The two-year study, to be conducted in the U.S., Europe, Hong Kong, Korea, and China, will be evaluate the effects of the drug candidate on glucose and hemoglobin A1c (HbA1c) in approximately 300 Type 2 patients currently taking metformin.

    In an earlier phase 2 study, PAZ320 achieved a 40 percent reduction in post-meal blood glucose levels with no serious adverse events.

    For additional information, visit BostonTI.com

    QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net

    Stocks: BTHE
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.